Reboxetine

Reboxetine

Reboxetine is a norepinephrine (noradrenaline) reuptake inhibitor (NRI) used in the treatment of depression, panic disorders and attention deficit hyperactivity disorder (ADHD). It is marketed under various trade names such as Edronax, Norebox, Prolift, Solvex, Davedax or Vestra.

Pharmacology

Reboxetine is a selective norepinephrine reuptake inhibitor, meaning it specifically targets the norepinephrine transporter (NET) and prevents the reuptake of norepinephrine into the presynaptic neuron. This increases the amount of norepinephrine available in the synaptic cleft to bind to postsynaptic receptors, leading to increased noradrenergic neurotransmission.

Clinical Use

Reboxetine is primarily used in the treatment of major depressive disorder. It may also be used off-label in the treatment of panic disorders and ADHD. The efficacy of reboxetine for depression is comparable to other antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs).

Side Effects

Common side effects of reboxetine include dry mouth, constipation, increased sweating, insomnia, and urinary retention. Less common side effects may include tachycardia, hypotension, and sexual dysfunction.

History

Reboxetine was first approved for use in Europe in 1997 and is currently available in many countries worldwide. However, it is not approved for use in the United States.

See Also

• Antidepressant
• Norepinephrine reuptake inhibitor
• Major depressive disorder
• Panic disorder
• Attention deficit hyperactivity disorder

‎